nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—SLCO2B1—Glyburide—gestational diabetes	0.432	0.518	CbGbCtD
Erlotinib—ABCG2—Glyburide—gestational diabetes	0.178	0.213	CbGbCtD
Erlotinib—ALB—Glyburide—gestational diabetes	0.122	0.147	CbGbCtD
Erlotinib—ABCB1—Glyburide—gestational diabetes	0.064	0.0767	CbGbCtD
Erlotinib—CYP3A4—Glyburide—gestational diabetes	0.0384	0.046	CbGbCtD
Erlotinib—PIP4K2C—islet of Langerhans—gestational diabetes	0.00408	0.036	CbGeAlD
Erlotinib—JAK3—adipose tissue—gestational diabetes	0.00366	0.0322	CbGeAlD
Erlotinib—LTK—head—gestational diabetes	0.00351	0.031	CbGeAlD
Erlotinib—NR1I2—head—gestational diabetes	0.00351	0.031	CbGeAlD
Erlotinib—SLK—islet of Langerhans—gestational diabetes	0.00348	0.0307	CbGeAlD
Erlotinib—TNK1—uterus—gestational diabetes	0.00343	0.0303	CbGeAlD
Erlotinib—AURKC—head—gestational diabetes	0.00303	0.0267	CbGeAlD
Erlotinib—JAK3—head—gestational diabetes	0.00281	0.0248	CbGeAlD
Erlotinib—EPHA6—head—gestational diabetes	0.00281	0.0248	CbGeAlD
Erlotinib—TNK1—vagina—gestational diabetes	0.00279	0.0246	CbGeAlD
Erlotinib—ABL2—adipose tissue—gestational diabetes	0.00275	0.0243	CbGeAlD
Erlotinib—EGFR—uterus—gestational diabetes	0.00275	0.0242	CbGeAlD
Erlotinib—EGFR—adipose tissue—gestational diabetes	0.00269	0.0237	CbGeAlD
Erlotinib—PIP4K2C—adipose tissue—gestational diabetes	0.0026	0.023	CbGeAlD
Erlotinib—MAP3K19—head—gestational diabetes	0.00255	0.0225	CbGeAlD
Erlotinib—ULK3—uterus—gestational diabetes	0.00254	0.0224	CbGeAlD
Erlotinib—ULK3—adipose tissue—gestational diabetes	0.00249	0.0219	CbGeAlD
Erlotinib—MKNK1—adipose tissue—gestational diabetes	0.00234	0.0206	CbGeAlD
Erlotinib—ABL2—vagina—gestational diabetes	0.00229	0.0202	CbGeAlD
Erlotinib—SLK—uterus—gestational diabetes	0.00227	0.02	CbGeAlD
Erlotinib—SLK—adipose tissue—gestational diabetes	0.00222	0.0195	CbGeAlD
Erlotinib—PIP4K2C—vagina—gestational diabetes	0.00217	0.0191	CbGeAlD
Erlotinib—ABL1—islet of Langerhans—gestational diabetes	0.00208	0.0184	CbGeAlD
Erlotinib—ULK3—vagina—gestational diabetes	0.00207	0.0182	CbGeAlD
Erlotinib—ABL1—embryo—gestational diabetes	0.00201	0.0178	CbGeAlD
Erlotinib—PIP4K2C—head—gestational diabetes	0.002	0.0176	CbGeAlD
Erlotinib—STK10—uterus—gestational diabetes	0.00197	0.0174	CbGeAlD
Erlotinib—MKNK1—vagina—gestational diabetes	0.00195	0.0172	CbGeAlD
Erlotinib—STK10—adipose tissue—gestational diabetes	0.00193	0.017	CbGeAlD
Erlotinib—ULK3—head—gestational diabetes	0.00191	0.0168	CbGeAlD
Erlotinib—SLK—vagina—gestational diabetes	0.00184	0.0163	CbGeAlD
Erlotinib—MKNK1—head—gestational diabetes	0.0018	0.0159	CbGeAlD
Erlotinib—MAP2K5—adipose tissue—gestational diabetes	0.00172	0.0152	CbGeAlD
Erlotinib—STK10—vagina—gestational diabetes	0.0016	0.0141	CbGeAlD
Erlotinib—STK10—head—gestational diabetes	0.00148	0.0131	CbGeAlD
Erlotinib—MAP2K5—vagina—gestational diabetes	0.00143	0.0126	CbGeAlD
Erlotinib—SLCO2B1—uterus—gestational diabetes	0.00137	0.0121	CbGeAlD
Erlotinib—ABL1—uterus—gestational diabetes	0.00136	0.012	CbGeAlD
Erlotinib—SLCO2B1—adipose tissue—gestational diabetes	0.00134	0.0118	CbGeAlD
Erlotinib—ABL1—adipose tissue—gestational diabetes	0.00133	0.0117	CbGeAlD
Erlotinib—MAP2K5—head—gestational diabetes	0.00132	0.0117	CbGeAlD
Erlotinib—Hepatic failure—Glyburide—gestational diabetes	0.00123	0.0606	CcSEcCtD
Erlotinib—Haemolytic anaemia—Glyburide—gestational diabetes	0.00122	0.0603	CcSEcCtD
Erlotinib—CYP3A5—islet of Langerhans—gestational diabetes	0.00122	0.0107	CbGeAlD
Erlotinib—Renal failure acute—Glyburide—gestational diabetes	0.00119	0.059	CcSEcCtD
Erlotinib—Renal impairment—Glyburide—gestational diabetes	0.00116	0.0572	CcSEcCtD
Erlotinib—Dermatitis bullous—Glyburide—gestational diabetes	0.00115	0.057	CcSEcCtD
Erlotinib—CYP1B1—uterus—gestational diabetes	0.00115	0.0101	CbGeAlD
Erlotinib—CYP1B1—adipose tissue—gestational diabetes	0.00112	0.00992	CbGeAlD
Erlotinib—ABL1—vagina—gestational diabetes	0.0011	0.00974	CbGeAlD
Erlotinib—SLCO2B1—head—gestational diabetes	0.00103	0.00907	CbGeAlD
Erlotinib—ABL1—head—gestational diabetes	0.00102	0.00899	CbGeAlD
Erlotinib—Pancreatitis—Glyburide—gestational diabetes	0.000934	0.0461	CcSEcCtD
Erlotinib—CYP1B1—head—gestational diabetes	0.000864	0.00762	CbGeAlD
Erlotinib—ABCG2—uterus—gestational diabetes	0.000856	0.00755	CbGeAlD
Erlotinib—ABCG2—adipose tissue—gestational diabetes	0.000837	0.00739	CbGeAlD
Erlotinib—CYP1A1—uterus—gestational diabetes	0.000813	0.00717	CbGeAlD
Erlotinib—CYP1A1—adipose tissue—gestational diabetes	0.000795	0.00701	CbGeAlD
Erlotinib—CYP3A5—adipose tissue—gestational diabetes	0.000777	0.00686	CbGeAlD
Erlotinib—Hepatitis—Glyburide—gestational diabetes	0.000762	0.0377	CcSEcCtD
Erlotinib—CYP2C8—vagina—gestational diabetes	0.000716	0.00631	CbGeAlD
Erlotinib—Eye disorder—Glyburide—gestational diabetes	0.000712	0.0352	CcSEcCtD
Erlotinib—ABCG2—vagina—gestational diabetes	0.000696	0.00614	CbGeAlD
Erlotinib—Alopecia—Glyburide—gestational diabetes	0.000674	0.0333	CcSEcCtD
Erlotinib—Erythema—Glyburide—gestational diabetes	0.000664	0.0328	CcSEcCtD
Erlotinib—Malnutrition—Glyburide—gestational diabetes	0.000664	0.0328	CcSEcCtD
Erlotinib—CYP1A1—vagina—gestational diabetes	0.000661	0.00583	CbGeAlD
Erlotinib—ABCB1—islet of Langerhans—gestational diabetes	0.000647	0.00571	CbGeAlD
Erlotinib—CYP3A5—vagina—gestational diabetes	0.000646	0.0057	CbGeAlD
Erlotinib—ABCB1—embryo—gestational diabetes	0.000626	0.00552	CbGeAlD
Erlotinib—CYP1A1—head—gestational diabetes	0.00061	0.00538	CbGeAlD
Erlotinib—Myalgia—Glyburide—gestational diabetes	0.000565	0.0279	CcSEcCtD
Erlotinib—Arthralgia—Glyburide—gestational diabetes	0.000565	0.0279	CcSEcCtD
Erlotinib—Oedema—Glyburide—gestational diabetes	0.000542	0.0268	CcSEcCtD
Erlotinib—Shock—Glyburide—gestational diabetes	0.000533	0.0263	CcSEcCtD
Erlotinib—Nervous system disorder—Glyburide—gestational diabetes	0.000531	0.0262	CcSEcCtD
Erlotinib—Thrombocytopenia—Glyburide—gestational diabetes	0.00053	0.0262	CcSEcCtD
Erlotinib—Anorexia—Glyburide—gestational diabetes	0.000516	0.0255	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Glyburide—gestational diabetes	0.000493	0.0244	CcSEcCtD
Erlotinib—Dyspnoea—Glyburide—gestational diabetes	0.000483	0.0239	CcSEcCtD
Erlotinib—Dyspepsia—Glyburide—gestational diabetes	0.000477	0.0236	CcSEcCtD
Erlotinib—Decreased appetite—Glyburide—gestational diabetes	0.000471	0.0233	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Glyburide—gestational diabetes	0.000468	0.0231	CcSEcCtD
Erlotinib—Gastrointestinal pain—Glyburide—gestational diabetes	0.000443	0.0219	CcSEcCtD
Erlotinib—CYP2D6—head—gestational diabetes	0.000441	0.00389	CbGeAlD
Erlotinib—Abdominal pain—Glyburide—gestational diabetes	0.000428	0.0212	CcSEcCtD
Erlotinib—ABCB1—uterus—gestational diabetes	0.000422	0.00372	CbGeAlD
Erlotinib—ABCB1—adipose tissue—gestational diabetes	0.000413	0.00364	CbGeAlD
Erlotinib—CYP1B1—Tryptophan metabolism—CYP19A1—gestational diabetes	0.000412	0.013	CbGpPWpGaD
Erlotinib—Asthenia—Glyburide—gestational diabetes	0.000389	0.0192	CcSEcCtD
Erlotinib—ABCG2—HIF-1-alpha transcription factor network—GCK—gestational diabetes	0.000384	0.0122	CbGpPWpGaD
Erlotinib—Pruritus—Glyburide—gestational diabetes	0.000383	0.0189	CcSEcCtD
Erlotinib—Diarrhoea—Glyburide—gestational diabetes	0.000371	0.0183	CcSEcCtD
Erlotinib—MAP2K5—MAPK Signaling Pathway—GCK—gestational diabetes	0.000363	0.0115	CbGpPWpGaD
Erlotinib—MAP2K5—Cardiac Hypertrophic Response—FGF2—gestational diabetes	0.000345	0.0109	CbGpPWpGaD
Erlotinib—Vomiting—Glyburide—gestational diabetes	0.000344	0.017	CcSEcCtD
Erlotinib—ABCB1—vagina—gestational diabetes	0.000343	0.00303	CbGeAlD
Erlotinib—Rash—Glyburide—gestational diabetes	0.000341	0.0169	CcSEcCtD
Erlotinib—Dermatitis—Glyburide—gestational diabetes	0.000341	0.0169	CcSEcCtD
Erlotinib—Headache—Glyburide—gestational diabetes	0.000339	0.0168	CcSEcCtD
Erlotinib—CYP1B1—Cytochrome P450 - arranged by substrate type—CYP19A1—gestational diabetes	0.000333	0.0105	CbGpPWpGaD
Erlotinib—CYP1B1—Oxidation by Cytochrome P450—CYP19A1—gestational diabetes	0.000329	0.0104	CbGpPWpGaD
Erlotinib—ALB—FOXA2 and FOXA3 transcription factor networks—GCK—gestational diabetes	0.000328	0.0104	CbGpPWpGaD
Erlotinib—Nausea—Glyburide—gestational diabetes	0.000322	0.0159	CcSEcCtD
Erlotinib—ABCB1—head—gestational diabetes	0.000317	0.0028	CbGeAlD
Erlotinib—CYP1A2—Phase II conjugation—GGCT—gestational diabetes	0.000277	0.00876	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—GCK—gestational diabetes	0.000273	0.00863	CbGpPWpGaD
Erlotinib—CYP1B1—Phase 1 - Functionalization of compounds—CYP19A1—gestational diabetes	0.00027	0.00855	CbGpPWpGaD
Erlotinib—CYP3A5—Biological oxidations—GGCT—gestational diabetes	0.000269	0.00851	CbGpPWpGaD
Erlotinib—SLCO2B1—SLC-mediated transmembrane transport—GCK—gestational diabetes	0.000264	0.00836	CbGpPWpGaD
Erlotinib—EGFR—Signaling events mediated by PTP1B—LEP—gestational diabetes	0.000255	0.00806	CbGpPWpGaD
Erlotinib—CYP1A1—Biological oxidations—GGCT—gestational diabetes	0.000254	0.00804	CbGpPWpGaD
Erlotinib—CYP1A1—Tryptophan metabolism—CYP19A1—gestational diabetes	0.000254	0.00804	CbGpPWpGaD
Erlotinib—MAP2K5—MicroRNAs in cardiomyocyte hypertrophy—FGF2—gestational diabetes	0.000246	0.00778	CbGpPWpGaD
Erlotinib—MKNK1—Signaling by FGFR—FGF2—gestational diabetes	0.000236	0.00748	CbGpPWpGaD
Erlotinib—CYP2C8—Biological oxidations—GGCT—gestational diabetes	0.000233	0.00737	CbGpPWpGaD
Erlotinib—EGFR—Androgen receptor signaling pathway—AR—gestational diabetes	0.000231	0.0073	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—GCK—gestational diabetes	0.00023	0.00728	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—ADIPOQ—gestational diabetes	0.000225	0.00711	CbGpPWpGaD
Erlotinib—MKNK1—Signaling by FGFR in disease—FGF2—gestational diabetes	0.00022	0.00697	CbGpPWpGaD
Erlotinib—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP19A1—gestational diabetes	0.000217	0.00688	CbGpPWpGaD
Erlotinib—CYP3A5—Oxidation by Cytochrome P450—CYP19A1—gestational diabetes	0.000214	0.00679	CbGpPWpGaD
Erlotinib—MAP2K5—Cardiac Hypertrophic Response—TNF—gestational diabetes	0.00021	0.00665	CbGpPWpGaD
Erlotinib—ABCB1—HIF-1-alpha transcription factor network—GCK—gestational diabetes	0.000208	0.00658	CbGpPWpGaD
Erlotinib—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP19A1—gestational diabetes	0.000205	0.0065	CbGpPWpGaD
Erlotinib—CYP1A1—Oxidation by Cytochrome P450—CYP19A1—gestational diabetes	0.000203	0.00641	CbGpPWpGaD
Erlotinib—ABCG2—HIF-1-alpha transcription factor network—LEP—gestational diabetes	0.000197	0.00622	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—GCK—gestational diabetes	0.000195	0.00617	CbGpPWpGaD
Erlotinib—CYP2D6—Biological oxidations—GGCT—gestational diabetes	0.000191	0.00605	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—ADIPOQ—gestational diabetes	0.000189	0.00599	CbGpPWpGaD
Erlotinib—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP19A1—gestational diabetes	0.000188	0.00596	CbGpPWpGaD
Erlotinib—CYP2C8—Oxidation by Cytochrome P450—CYP19A1—gestational diabetes	0.000186	0.00588	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—CYP19A1—gestational diabetes	0.000182	0.00575	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—AR—gestational diabetes	0.000177	0.00559	CbGpPWpGaD
Erlotinib—CYP3A5—Phase 1 - Functionalization of compounds—CYP19A1—gestational diabetes	0.000176	0.00557	CbGpPWpGaD
Erlotinib—NR1I2—Generic Transcription Pathway—AR—gestational diabetes	0.000167	0.00529	CbGpPWpGaD
Erlotinib—CYP1A1—Phase 1 - Functionalization of compounds—CYP19A1—gestational diabetes	0.000166	0.00527	CbGpPWpGaD
Erlotinib—CYP1A2—Biological oxidations—GGCT—gestational diabetes	0.000162	0.00513	CbGpPWpGaD
Erlotinib—CYP1A2—Tryptophan metabolism—CYP19A1—gestational diabetes	0.000162	0.00512	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—CYP19A1—gestational diabetes	0.000155	0.00491	CbGpPWpGaD
Erlotinib—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—gestational diabetes	0.000155	0.00489	CbGpPWpGaD
Erlotinib—UGT1A1—Biological oxidations—CYP19A1—gestational diabetes	0.000154	0.00487	CbGpPWpGaD
Erlotinib—CYP2C8—Phase 1 - Functionalization of compounds—CYP19A1—gestational diabetes	0.000153	0.00483	CbGpPWpGaD
Erlotinib—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—gestational diabetes	0.000152	0.00483	CbGpPWpGaD
Erlotinib—UGT1A1—Metapathway biotransformation—CYP19A1—gestational diabetes	0.000152	0.0048	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—AR—gestational diabetes	0.000151	0.00478	CbGpPWpGaD
Erlotinib—MAP2K5—MicroRNAs in cardiomyocyte hypertrophy—TNF—gestational diabetes	0.00015	0.00474	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—AR—gestational diabetes	0.000146	0.00463	CbGpPWpGaD
Erlotinib—CYP1B1—Biological oxidations—CYP19A1—gestational diabetes	0.000144	0.00454	CbGpPWpGaD
Erlotinib—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—gestational diabetes	0.000143	0.00453	CbGpPWpGaD
Erlotinib—CYP1B1—Metapathway biotransformation—CYP19A1—gestational diabetes	0.000142	0.00448	CbGpPWpGaD
Erlotinib—MKNK1—MAPK Signaling Pathway—TNF—gestational diabetes	0.00014	0.00443	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—LEP—gestational diabetes	0.000139	0.00441	CbGpPWpGaD
Erlotinib—ABL1—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—gestational diabetes	0.000136	0.0043	CbGpPWpGaD
Erlotinib—SLCO2B1—Transmembrane transport of small molecules—GCK—gestational diabetes	0.000134	0.00425	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—MTNR1B—gestational diabetes	0.000134	0.00425	CbGpPWpGaD
Erlotinib—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TNF—gestational diabetes	0.000133	0.00422	CbGpPWpGaD
Erlotinib—CYP1B1—Aryl Hydrocarbon Receptor—TNF—gestational diabetes	0.000133	0.00422	CbGpPWpGaD
Erlotinib—MKNK1—Disease—RBP4—gestational diabetes	0.000133	0.00421	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—LEP—gestational diabetes	0.000132	0.00419	CbGpPWpGaD
Erlotinib—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—gestational diabetes	0.000131	0.00414	CbGpPWpGaD
Erlotinib—EGFR—Aryl Hydrocarbon Receptor—TNF—gestational diabetes	0.00013	0.00411	CbGpPWpGaD
Erlotinib—EGFR—Aryl Hydrocarbon Receptor Pathway—TNF—gestational diabetes	0.00013	0.00411	CbGpPWpGaD
Erlotinib—EGFR—Constitutive PI3K/AKT Signaling in Cancer—FGF2—gestational diabetes	0.000129	0.0041	CbGpPWpGaD
Erlotinib—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—gestational diabetes	0.000129	0.00409	CbGpPWpGaD
Erlotinib—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—gestational diabetes	0.000125	0.00396	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—AR—gestational diabetes	0.000125	0.00396	CbGpPWpGaD
Erlotinib—CYP3A4—Biological oxidations—GGCT—gestational diabetes	0.000125	0.00396	CbGpPWpGaD
Erlotinib—CYP3A4—Tryptophan metabolism—CYP19A1—gestational diabetes	0.000125	0.00395	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—MTNR1B—gestational diabetes	0.000122	0.00386	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—LEPR—gestational diabetes	0.000121	0.00382	CbGpPWpGaD
Erlotinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—FGF2—gestational diabetes	0.00012	0.0038	CbGpPWpGaD
Erlotinib—MKNK1—Disease—NAMPT—gestational diabetes	0.000119	0.00377	CbGpPWpGaD
Erlotinib—MKNK1—Disease—GCK—gestational diabetes	0.000118	0.00375	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—LEP—gestational diabetes	0.000118	0.00372	CbGpPWpGaD
Erlotinib—EGFR—PI-3K cascade—FGF2—gestational diabetes	0.000117	0.00369	CbGpPWpGaD
Erlotinib—EGFR—PI3K/AKT activation—FGF2—gestational diabetes	0.000114	0.0036	CbGpPWpGaD
Erlotinib—EGFR—GAB1 signalosome—FGF2—gestational diabetes	0.000113	0.00357	CbGpPWpGaD
Erlotinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—FGF2—gestational diabetes	0.00011	0.00349	CbGpPWpGaD
Erlotinib—JAK3—Immune System—MBL2—gestational diabetes	0.000108	0.00341	CbGpPWpGaD
Erlotinib—ABCB1—HIF-1-alpha transcription factor network—LEP—gestational diabetes	0.000106	0.00336	CbGpPWpGaD
Erlotinib—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—gestational diabetes	0.000106	0.00336	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—FGF2—gestational diabetes	0.000106	0.00335	CbGpPWpGaD
Erlotinib—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—gestational diabetes	0.000101	0.0032	CbGpPWpGaD
Erlotinib—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—gestational diabetes	9.97e-05	0.00315	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—GCK—gestational diabetes	9.63e-05	0.00305	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MTNR1B—gestational diabetes	9.55e-05	0.00302	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—MBL2—gestational diabetes	9.46e-05	0.00299	CbGpPWpGaD
Erlotinib—CYP3A5—Biological oxidations—CYP19A1—gestational diabetes	9.36e-05	0.00296	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—RBP4—gestational diabetes	9.31e-05	0.00294	CbGpPWpGaD
Erlotinib—CYP3A5—Metapathway biotransformation—CYP19A1—gestational diabetes	9.23e-05	0.00292	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—FGF2—gestational diabetes	9.22e-05	0.00292	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—LEPR—gestational diabetes	9.11e-05	0.00288	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—FGF2—gestational diabetes	8.93e-05	0.00283	CbGpPWpGaD
Erlotinib—CYP1A1—Biological oxidations—CYP19A1—gestational diabetes	8.84e-05	0.0028	CbGpPWpGaD
Erlotinib—CYP1A1—Metapathway biotransformation—CYP19A1—gestational diabetes	8.72e-05	0.00276	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—FGF2—gestational diabetes	8.72e-05	0.00276	CbGpPWpGaD
Erlotinib—MAP2K5—MAPK Signaling Pathway—TNF—gestational diabetes	8.6e-05	0.00272	CbGpPWpGaD
Erlotinib—EGFR—Regulation of Actin Cytoskeleton—FGF2—gestational diabetes	8.34e-05	0.00264	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—FGF2—gestational diabetes	8.34e-05	0.00264	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—GCK—gestational diabetes	8.23e-05	0.0026	CbGpPWpGaD
Erlotinib—CYP1A1—Aryl Hydrocarbon Receptor—TNF—gestational diabetes	8.22e-05	0.0026	CbGpPWpGaD
Erlotinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—gestational diabetes	8.22e-05	0.0026	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—FGF2—gestational diabetes	8.21e-05	0.0026	CbGpPWpGaD
Erlotinib—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—gestational diabetes	8.19e-05	0.00259	CbGpPWpGaD
Erlotinib—CYP2C8—Biological oxidations—CYP19A1—gestational diabetes	8.11e-05	0.00256	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—MBL2—gestational diabetes	8.08e-05	0.00256	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—AR—gestational diabetes	8.05e-05	0.00255	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—FGF2—gestational diabetes	8e-05	0.00253	CbGpPWpGaD
Erlotinib—CYP2C8—Metapathway biotransformation—CYP19A1—gestational diabetes	7.99e-05	0.00253	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—ADIPOQ—gestational diabetes	7.93e-05	0.00251	CbGpPWpGaD
Erlotinib—ALB—SLC-mediated transmembrane transport—GCK—gestational diabetes	7.92e-05	0.00251	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—FGF2—gestational diabetes	7.84e-05	0.00248	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—FGF2—gestational diabetes	7.8e-05	0.00247	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—FGF2—gestational diabetes	7.76e-05	0.00246	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—FGF2—gestational diabetes	7.72e-05	0.00244	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—FGF2—gestational diabetes	7.61e-05	0.00241	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—GGCT—gestational diabetes	7.56e-05	0.00239	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—LEPR—gestational diabetes	7.43e-05	0.00235	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—FGF2—gestational diabetes	7.27e-05	0.0023	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—FGF2—gestational diabetes	7.27e-05	0.0023	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—FGF2—gestational diabetes	7.27e-05	0.0023	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—FGF2—gestational diabetes	7.2e-05	0.00228	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MTNR1B—gestational diabetes	7.2e-05	0.00228	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—FGF2—gestational diabetes	7.14e-05	0.00226	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—FGF2—gestational diabetes	7.11e-05	0.00225	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GGCT—gestational diabetes	7.06e-05	0.00223	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—RBP4—gestational diabetes	7.02e-05	0.00222	CbGpPWpGaD
Erlotinib—ALB—Vitamin B12 Metabolism—TNF—gestational diabetes	6.9e-05	0.00218	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—FGF2—gestational diabetes	6.84e-05	0.00216	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—ADIPOQ—gestational diabetes	6.77e-05	0.00214	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—FGF2—gestational diabetes	6.72e-05	0.00213	CbGpPWpGaD
Erlotinib—CYP2D6—Biological oxidations—CYP19A1—gestational diabetes	6.65e-05	0.00211	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—GLS2—gestational diabetes	6.61e-05	0.00209	CbGpPWpGaD
Erlotinib—CYP2D6—Metapathway biotransformation—CYP19A1—gestational diabetes	6.56e-05	0.00208	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—GCK—gestational diabetes	6.52e-05	0.00206	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—TNF—gestational diabetes	6.45e-05	0.00204	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—FGF2—gestational diabetes	6.44e-05	0.00204	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GGCT—gestational diabetes	6.42e-05	0.00203	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AR—gestational diabetes	6.32e-05	0.002	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GLS2—gestational diabetes	6.17e-05	0.00195	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—TNF—gestational diabetes	6.12e-05	0.00194	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MTNR1B—gestational diabetes	5.87e-05	0.00186	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—RBP4—gestational diabetes	5.72e-05	0.00181	CbGpPWpGaD
Erlotinib—CYP1A2—Biological oxidations—CYP19A1—gestational diabetes	5.64e-05	0.00178	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—TNF—gestational diabetes	5.61e-05	0.00178	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GLS2—gestational diabetes	5.61e-05	0.00178	CbGpPWpGaD
Erlotinib—CYP1A2—Metapathway biotransformation—CYP19A1—gestational diabetes	5.56e-05	0.00176	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—CYP19A1—gestational diabetes	5.51e-05	0.00174	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MBL2—gestational diabetes	5.51e-05	0.00174	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—TNF—gestational diabetes	5.44e-05	0.00172	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—MTNR1B—gestational diabetes	5.33e-05	0.00169	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—gestational diabetes	5.24e-05	0.00166	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—gestational diabetes	5.24e-05	0.00166	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—FGF2—gestational diabetes	4.95e-05	0.00157	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—LEP—gestational diabetes	4.92e-05	0.00156	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—gestational diabetes	4.87e-05	0.00154	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MBL2—gestational diabetes	4.71e-05	0.00149	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—TNF—gestational diabetes	4.61e-05	0.00146	CbGpPWpGaD
Erlotinib—MKNK1—Disease—FGF2—gestational diabetes	4.6e-05	0.00146	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GGCT—gestational diabetes	4.6e-05	0.00146	CbGpPWpGaD
Erlotinib—ALB—Selenium Micronutrient Network—TNF—gestational diabetes	4.46e-05	0.00141	CbGpPWpGaD
Erlotinib—EGFR—Disease—RBP4—gestational diabetes	4.38e-05	0.00139	CbGpPWpGaD
Erlotinib—CYP3A4—Biological oxidations—CYP19A1—gestational diabetes	4.35e-05	0.00138	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GGCT—gestational diabetes	4.34e-05	0.00137	CbGpPWpGaD
Erlotinib—CYP3A4—Metapathway biotransformation—CYP19A1—gestational diabetes	4.29e-05	0.00136	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—TNF—gestational diabetes	4.26e-05	0.00135	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—LEP—gestational diabetes	4.24e-05	0.00134	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—LEP—gestational diabetes	4.21e-05	0.00133	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—gestational diabetes	4.16e-05	0.00132	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—GCK—gestational diabetes	4.02e-05	0.00127	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GLS2—gestational diabetes	4.02e-05	0.00127	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—LEPR—gestational diabetes	3.98e-05	0.00126	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GGCT—gestational diabetes	3.98e-05	0.00126	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GGCT—gestational diabetes	3.96e-05	0.00125	CbGpPWpGaD
Erlotinib—EGFR—Disease—NAMPT—gestational diabetes	3.93e-05	0.00124	CbGpPWpGaD
Erlotinib—EGFR—Disease—GCK—gestational diabetes	3.91e-05	0.00124	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GLS2—gestational diabetes	3.8e-05	0.0012	CbGpPWpGaD
Erlotinib—JAK3—Immune System—FGF2—gestational diabetes	3.76e-05	0.00119	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—FGF2—gestational diabetes	3.74e-05	0.00118	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—NAMPT—gestational diabetes	3.62e-05	0.00115	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—GCK—gestational diabetes	3.6e-05	0.00114	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—GCK—gestational diabetes	3.53e-05	0.00112	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GLS2—gestational diabetes	3.48e-05	0.0011	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GGCT—gestational diabetes	3.47e-05	0.0011	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GLS2—gestational diabetes	3.46e-05	0.0011	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—gestational diabetes	3.45e-05	0.00109	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—CYP19A1—gestational diabetes	3.39e-05	0.00107	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—NAMPT—gestational diabetes	3.38e-05	0.00107	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GCK—gestational diabetes	3.36e-05	0.00106	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—FGF2—gestational diabetes	3.3e-05	0.00105	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GGCT—gestational diabetes	3.27e-05	0.00103	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—FGF2—gestational diabetes	3.22e-05	0.00102	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—LEP—gestational diabetes	3.2e-05	0.00101	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—FGF2—gestational diabetes	3.2e-05	0.00101	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MTNR1B—gestational diabetes	3.15e-05	0.000997	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—gestational diabetes	3.11e-05	0.000985	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—CYP19A1—gestational diabetes	3.09e-05	0.000979	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—NAMPT—gestational diabetes	3.07e-05	0.000973	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—RBP4—gestational diabetes	3.07e-05	0.000971	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GCK—gestational diabetes	3.05e-05	0.000967	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GLS2—gestational diabetes	3.03e-05	0.00096	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GLS2—gestational diabetes	2.86e-05	0.000905	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—FGF2—gestational diabetes	2.82e-05	0.000893	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GGCT—gestational diabetes	2.77e-05	0.000877	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—FGF2—gestational diabetes	2.71e-05	0.000858	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CYP19A1—gestational diabetes	2.63e-05	0.000833	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—LEP—gestational diabetes	2.61e-05	0.000825	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CYP19A1—gestational diabetes	2.46e-05	0.000777	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—FGF2—gestational diabetes	2.43e-05	0.000769	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GLS2—gestational diabetes	2.42e-05	0.000766	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—TNF—gestational diabetes	2.28e-05	0.000721	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CYP19A1—gestational diabetes	2.23e-05	0.000707	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NAMPT—gestational diabetes	2.2e-05	0.000697	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GCK—gestational diabetes	2.19e-05	0.000693	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—gestational diabetes	2.16e-05	0.000685	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GGCT—gestational diabetes	2.14e-05	0.000677	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—gestational diabetes	2.1e-05	0.000665	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NAMPT—gestational diabetes	2.08e-05	0.000658	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GCK—gestational diabetes	2.07e-05	0.000654	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FGF2—gestational diabetes	1.98e-05	0.000627	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—TNF—gestational diabetes	1.95e-05	0.000616	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FGF2—gestational diabetes	1.92e-05	0.000609	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NAMPT—gestational diabetes	1.91e-05	0.000604	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NAMPT—gestational diabetes	1.9e-05	0.0006	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GCK—gestational diabetes	1.9e-05	0.0006	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GCK—gestational diabetes	1.88e-05	0.000596	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GLS2—gestational diabetes	1.87e-05	0.000591	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NAMPT—gestational diabetes	1.66e-05	0.000526	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GCK—gestational diabetes	1.65e-05	0.000523	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FGF2—gestational diabetes	1.64e-05	0.00052	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CYP19A1—gestational diabetes	1.6e-05	0.000506	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NAMPT—gestational diabetes	1.57e-05	0.000496	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GCK—gestational diabetes	1.56e-05	0.000492	CbGpPWpGaD
Erlotinib—EGFR—Disease—FGF2—gestational diabetes	1.52e-05	0.00048	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CYP19A1—gestational diabetes	1.51e-05	0.000478	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—LEP—gestational diabetes	1.4e-05	0.000443	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP19A1—gestational diabetes	1.39e-05	0.000439	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP19A1—gestational diabetes	1.38e-05	0.000436	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NAMPT—gestational diabetes	1.33e-05	0.00042	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GCK—gestational diabetes	1.32e-05	0.000417	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP19A1—gestational diabetes	1.21e-05	0.000382	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP19A1—gestational diabetes	1.14e-05	0.00036	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGF2—gestational diabetes	1.06e-05	0.000336	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NAMPT—gestational diabetes	1.02e-05	0.000324	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GCK—gestational diabetes	1.02e-05	0.000322	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP19A1—gestational diabetes	9.64e-06	0.000305	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP19A1—gestational diabetes	7.44e-06	0.000235	CbGpPWpGaD
